Periodontal surgery using rhFGF‐2 with deproteinized bovine bone mineral or rhFGF‐2 alone: 2‐year follow‐up of a randomized controlled trial.

Autor:	Aoki, Hideto, Bizenjima, Takahiro, Seshima, Fumi, Sato, Masahiro, Irokawa, Daisuke, Yoshikawa, Kouki, Yoshida, Wataru, Imamura, Kentaro, Matsugami, Daisuke, Kitamura, Yurie, Kita, Daichi, Sugito, Hiroki, Tomita, Sachiyo, Saito, Atsushi
Předmět:	PERIODONTITIS treatment FIBROBLAST growth factor 2 MINERAL content of bones BOVINE anatomy BONE surgery TRAUMATIC bone defects AUTOGRAFTS BONE regeneration BONE substitutes BONE grafting COMPARATIVE studies GROWTH factors GUIDED tissue regeneration PATIENT aftercare ORAL surgery HEALTH outcome assessment PERIODONTITIS POSTOPERATIVE period TREATMENT effectiveness DESCRIPTIVE statistics
Zdroj:	Journal of Clinical Periodontology; Jan2021, Vol. 48 Issue 1, p91-99, 9p, 1 Color Photograph, 3 Charts, 2 Graphs
Abstrakt:	Aim: To compare outcomes of rhFGF‐2 + DBBM therapy with rhFGF‐2 alone in the treatment of intrabony defects. This study provides 2‐year follow‐up results from the previous randomized controlled trial. Materials and Methods: Defects were randomly allocated to receive rhFGF‐2 + DBBM (test) or rhFGF‐2 (control). Treated sites were re‐evaluated at 2 years postoperatively, using original clinical and patient‐centred measures. Results: Thirty‐eight sites were available for re‐evaluation. At 2 years, both groups showed a significant improvement in clinical attachment level (CAL) from baseline. A gain in CAL of 3.4 ± 1.3 mm in the test group and 3.1 ± 1.5 mm in the control group was found. No significant inter‐group difference was noted. Both groups showed a progressive increase in radiographic bone fill (RBF). The test treatment yielded greater RBF (56%) compared with the control group (41%). The control treatment performed better in contained defects in terms of CAL and RBF. There was no significant difference in patient‐reported outcomes between groups. Conclusions: At 2‐year follow‐up, the test and cotrol treatments were similarly effective in improving CAL, whereas the test treatment achieved a significantly greater RBF. In both treatments, favourable clinical, radiographic, and patient‐reported outcomes can be sustained for at least 2 years. Trial registration: The University Hospital Medical Information Network‐Clinical Trials Registry (UMIN‐CTR) 000025257. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text